Companies will study drug effects at the molecular level through biomarkers and imaging tools.
N.V. Organon and Royal Philips Electronics are joining forces to develop drugs and therapies for mental disorders and cancer. The companies plan to use biomarkers and Philips’ noninvasive medical imaging technology to study the effects of drugs in the brain at the molecular level.
“Organon has invested heavily in optimizing its R&D efforts,” remarks David Nicholson, exceutive vp R&D of Organon. “We are convinced that biomarker research will accelerate the R&D process and improve the success rate of developing new molecular and biological therapies.”
As part of the agreement, scientists from Organon will work at the Philips Life Sciences facilities to identify, validate, and exploit novel biomarkers. “Our medical imaging modalities are rapidly improving and have evolved into extremely powerful tools to image the function and behavior of an anatomical feature, and not just its shape,” points out Rick Harwig, CTO of Philips.
“The combined technological expertise of Philips and the life sciences know-how of Organon will definitely speed up the evolution of our imaging modalities into tools to image the body at the molecular level. In addition, they will enable new opportunities in molecular diagnostics.”